MBF Therapeutics

MBFT’s goal is to become the leader in developing and commercializing next generation vaccines for the animal health market.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Ambler, PA, US
  • Currency USD
  • Founded June 2008
  • Employees 3
  • Incorporation Type C-corp
  • Website mbftherapeutics.com

Company Summary

MBFT is an immunotherapeutics company focused on animal applications of its innovative T-Max™ immunotherapeutic DNA vaccine platform. In addition, there are significant translational opportunities in human health. Our T-Max platform addresses significant shortcomings of traditional viral vaccine technologies such as killed virus and modified live virus vaccines. Our lead products are for PRRS, ASF and poultry diseases such as HPAI.

Team

  • Thomas Tillett
    Founder & CEO

    CEO of RHeoGene. Started the company in 1999 as a JV between Rohm & Haas and Argonex. In 2003, he led the highly innovative and unique effort to donate the IP and material assets of RHeoGene to the UPMC. As RheoGene CEO, he and his team established an innovative clinical development program with the RheoSwitch® Therapeutic System (RTS) that has led to the first human clinical trial of a small molecule-induced gene regulation system.

  • Lorraine Keller
    Chief Scientific Officer

    Founder & VP Marketing and Communications @ RheoGene
    Co-founder Immunotope
    Portfolio Manager, Biostrategy Partners
    Rohm and Haas Co.

  • Carl Johnson
    Chief Medical Officer

    CEO at Prairie Diagnostic Services, Inc., a full service veterinary diagnostic laboratory
    Chief Medical Officer at Premune
    Schering-Plough Animal Health, Pfizer AH (international HQ), Intervet, Inc., Baxter HealthCare and Merial
    DVM from Cornell University

  • Ron Cravens
    Executive Vice President Business Development

    President of Amlan International the Animal Health and Nutrition Division of family owned publicly traded sorbent mineral company from Chicago, Illinois.
    NOVARTIS ANIMAL VACCINES INC., President & CEO
    PFIZER ANIMAL HEALTH Marketing Director/Senior Marketing Manger, Global Biologicals
    SMITHKLINE BEECHAM ANIMAL HEALTH Director, Worldwide Strategic Product Development

Previous Investors

  • Ben Franklin Technology Partners SEPA
    Unconfirmed
    Chris Cashman
    Unconfirmed
    Gerald McNamara
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free